Nasal Human Abuse Potential of PTI-821

Summary

The study will evaluate the human abuse liability of PTI-821 (oxycodone extended-release capsules) when administered nasally compared to crushed oxycodone IR tablets and crushed OxyContin tablets, also administered nasally.

Timeline

Start

2017-05-15

Primary completion

2017-07-31

Completion

2017-12-15

Drugs

Indications